Study wrapper · #1076
Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide.
Saito C, Saito M, Nakagawa M, et al. Internal medicine (Tokyo, Japan). 2026.
DOI: 10.2169/internalmedicine.7502-26PubMed: 42543696
Editor's note
A single case cannot establish causation, and this patient also underwent sleeve gastrectomy, making the peptides' specific contribution impossible to isolate. It is a useful safety-awareness signal that rapid weight loss regimens may coincide with disordered-eating psychopathology in susceptible individuals. Regard it as hypothesis-generating rather than as evidence of a defined risk.
Plain-language abstract
This single case report describes a 60-year-old woman who developed atypical anorexia nervosa after bariatric surgery combined with semaglutide and tirzepatide. The authors note the co-occurrence but cannot establish that the medications were the cause.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026